研究者詳細 - 足立　剛也

論文 - 足立　剛也

分割表示 57 件中 1 - 20 件目／全件表示 >>

IgA vasculitis presenting with Achilles peritendinitis: A case report

Keita Hirata, Takeya Adachi, Saeko Takamiyagi, Masaki Arai, Yoshio Nakamura, Takeru Funakoshi, Masayuki Amagai, Akiko Tanikawa, Masatoshi Kawai, Ayano Fukushima‐Nomura

The Journal of Dermatology 2025年01月

Access to Document (DOI)

Research team diversity impacts scientific output in allergy and immunology programs

Takeya Adachi,, Norika Narimatsu, Yasushi Ogawa,, Masako Toriya,, Tamami Fukushi,, Masashi Shirabe,, Masaki Futamura,, Takenori Inomata,, Keigo Kainuma,, Keiko Kan-o,, Yosuke Kurashima,, Katsunori Masaki,, Saeko Nakajima,, Masafumi Sakashita,, Sakura Sato,, Mayumi Tamari,, Hideaki Morita,, Amane Koizumi,

World Allergy Organization Journal 2025年01月

Access to Document (DOI)

Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series

Takeya Adachi, Tomoya Matsui, Utako Okata‐Karigane, Chiaki Takahashi, Umi Tahara, Mari Hyodo, Akihiro Miyagawa, Kenta Kobayashi, Yoshio Nakamura, Takeru Funakoshi, Hiroshi Nishio, Wataru Yamagami, Hayato Takahashi

The Journal of Dermatology 2025年01月

Access to Document (DOI)

Minimal Clinically Important Differences With the Outcomes of the App-Based Japanese Allergic Conjunctival Diseases Quality of Life Questionnaire: Cross-Sectional Observational Study

Ken Nagino, Jaemyoung Sung, Akie Midorikawa-Inomata, Yasutsugu Akasaki, Takeya Adachi, Nobuyuki Ebihara, Ken Fukuda, Atsuki Fukushima, Kenta Fujio, Yuichi Okumura, Atsuko Eguchi, Keiichi Fujimoto, Hurramhon Shokirova, Alan Yee, Yuki Morooka, Tianxiang Huang, Kunihiko Hirosawa, Shintaro Nakao, Hiroyuki Kobayashi, Takenori Inomata

JMIR Formative Research 2024年11月

Access to Document (DOI)

Acidic oral environment’s potential contribution to palladium-induced systemic contact dermatitis: Case report

Takeya Adachi, Katsunori Masaki, Kazuyo Sujino, Utako Okata-Karigane, Taro Murakami, Chiaki Takahashi, Shiori Nakayama, Saki Tomiyasu, Masato Asaoka, Hiroki Kabata, Jun Miyata, Hayato Takahashi, Koichi Fukunaga

Journal of Allergy and Clinical Immunology: Global 2024年11月

Access to Document (DOI)

Successful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review

Misuzu Tsunoda, Takeya Adachi, Yuuri Nakajima, Yoshihiro Yatomi, Tomoko Shimizu, Katsuki Nakasute

Journal of Allergy and Clinical Immunology: Global 2024年11月

Access to Document (DOI)

The impact of COVID-19 on hay fever treatment in Japan: A retrospective cohort study based on the Japanese claims database.

Yasutsugu Akasaki, Takenori Inomata, Masao Iwagami, Jaemyoung Sung, Ken Nagino, Takeya Adachi, Hideaki Morita, Mayumi Tamari, Keigo Kainuma, Keiko Kan-O, Hiroaki Ogata, Masafumi Sakashita, Masaki Futamura, Yosuke Kurashima, Saeko Nakajima, Katsunori Masaki, Yasushi Ogawa, Sakura Sato, Akihiro Miyagawa, Akie Midorikawa-Inomata, Keiichi Fujimoto, Yuichi Okumura, Kenta Fujio, Tianxiang Huang, Kunihiko Hirosawa, Yuki Morooka, Akira Murakami, Shintaro Nakao

Clinical and translational allergy 14 （ 9 ） e12394 2024年09月

BACKGROUND: Hay fever (HF) presents with various symptoms, including allergic conjunctivitis and rhinitis, and requires cross-organ treatment. This study assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on HF treatment trends. METHODS: This retrospective cohort study utilized data from the JMDC database collected between January 2018 and May 2021. Patients with HF were identified based on the relevant International Classification of Diseases 10th Revision diagnosis codes and the prescription of HF-related medications. The treatment approaches were compared during the cedar and cypress pollen allergy season (January to May in Japan) before and during the COVID-19 pandemic (2018 and 2019, and 2020 and 2021, respectively). RESULTS: This study included 2,598,178 patients with HF. The numbers of prescribed HF-related claims in 2018, 2019, 2020, and 2021 were 3,332,854, 3,534,198, 2,774,380, and 2,786,681 times, respectively. Oral second-generation antihistamine prescriptions decreased by >10% from 2019 to 2020, with a <10% change in the subsequent year. Anti-allergic eye drop prescriptions also decreased by >10% from 2019 to 2020 but increased by >10% from 2020 to 2021. Compared with 2018, 2019, and 2020, the number of claims in the rhinitis symptoms dominant group was significantly decreased in 2021 (p < 0.001, all). In contrast, the number of claims in the eye symptoms dominant group and the rhinitis and eye symptoms dominant group increased in 2021 compared with that in 2018, 2019, and 2020 (p < 0.001, all). CONCLUSION: Changes in HF treatment and related outcomes could be attributed to lifestyle modifications resulting from the COVID-19 pandemic. Measures, such as limiting outdoor activities and adopting mask-wearing practices may have influenced HF symptoms, preventive behaviors, and the overall approach to treating HF.

Access to Document (DOI)

メトトレキサート過量内服により皮膚粘膜障害,汎血球減少を生じたSAPHO症候群の1例

梶間諒, 足立剛也, 宮川明大, 今井悠気, 花岡洋成, 野村彩乃, 高橋勇人, 天谷雅行, 大内健嗣

臨床皮膚科（(株)医学書院） 78 （ 10 ） 731 - 736 2024年09月

ISSN 0021-4973

＜文献概要＞66歳,女性.SAPHO症候群に対してメトトレキサート(MTX)内服中,関節痛増悪がありMTX 6mg/週から8mg/週に処方量を増量した.最終内服2日後に発熱,口唇・口腔内のびらん,背部の紅斑・びらんが出現した.血液検査ではHb 10.5g/dl,好中球数1,320/μl,血小板数5×104/μlと汎血球減少を認めた.詳細な薬歴聴取により,本人がMTXの内服方法を誤ったことを自覚しながら自己判断で内服を継続しており,MTXを32mg/週内服していたことが判明した.MTX休薬等の加療で最終内服11日後には皮膚・粘膜症状,汎血球減少は改善した.以上よりMTX急性毒性と診断した.MTXは内服法が特殊で認知機能に問題がなくても誤用する可能性がある.MTX過量内服による副作用を予防するためには内服方法,過量内服した際の対応,副作用に関して十分に指導することが必要である.

アレルギー領域における診療科・職種横断的リカレント教育の重要性　「出前授業による教育の機会創出事業」参加者データの分析

正木克宜, 坂下雅文, 小川靖, 猪俣武範, 貝沼圭吾, 神尾敬子, 佐藤さくら, 玉利真由美, 中島沙恵子, 森田英明, 倉島洋介, 二村昌樹, 高橋浩一郎, 春田淳志, 百武美沙, 門川俊明, 石塚全, 意元義政, 尾山徳孝, 神崎晶, 木戸口正典, 福島敦樹, 福永興壱, 藤枝重治, 安冨素子, 足立剛也, 免疫アレルギー疾患研究10か年戦略次世代タスクフォース(ENGAGE-TF)

アレルギー（(一社)日本アレルギー学会） 73 （ 4 ） 329 - 339 2024年06月

ISSN 0021-4884

【背景】多職種・複数診療科が関与するアレルギー診療水準の向上には,専門医以外も対象とした教育の必要性が考えられるが,そのニーズ調査と方法に関する検討は不十分である.【目的・方法】免疫アレルギー疾患研究10か年戦略次世代タスクフォース(ENGAGE-TF)は学会支援下に慶應義塾大学,福井大学と連携した複数回のバーチャル教育企画「出前授業」を企画した.そのニーズと有用性を検証するため,SNSや各大学・医師会等を通じて周知し,メーリングリストを用いてアンケート調査を行った.【結果】のべ1139人・回より回答を得た.半数以上が専門医以外の医師であり,幅広い医療関連職種も参加した.7割が「とても満足」,6割以上が「ちょうどよい」難易度と回答した.自由記載の感想から,職種毎の学びの焦点,経験年数による学びのスタンスの違いが見られた.【考察・結語】9割を占める専門医以外の参加者のプライマリケアにおけるアレルギー疾患対応ニーズの高さと,経験11年以上の医療関連職種の遠隔教育・リカレント教育の有用性が示唆された.(著者抄録)

Minimal Clinically Important Differences With the Outcomes of the App-Based Japanese Allergic Conjunctival Diseases Quality of Life Questionnaire: Cross-Sectional Observational Study (Preprint)

2024年05月

Access to Document (DOI)

足立剛也, 早野元詞, 伊藤靖典, 猪俣武範, 小川靖, 貝沼圭吾, 神尾敬子, 倉島洋介, 桑原優, 坂下雅文, 佐藤さくら, 富田康裕, 中島沙恵子, 二村昌樹, 正木克宜, 玉利真由美, 海老澤元宏, 森田英明, 日本アレルギー学会医療戦略検討委員会

アレルギー（(一社)日本アレルギー学会） 73 （ 3 ） 268 - 278 2024年05月

ISSN 0021-4884

【背景】2022年「新しい資本主義のグランドデザイン及び実行計画」が閣議決定され,スタートアップ等の推進・環境整備が始まった中,アレルギー領域の国内外のスタートアップ投資状況の調査は喫緊の課題と言える.【方法】2010-2021年までの日米欧のアレルギー関連スタートアップ156社を対象に,データベースやVCウェブサイトから投資情報等を集計した.【結果】投資額は7.2億USDで,米国:欧州:日本の比率は20:6:1であった.米国は2016-2018年をピークに鈍化する一方,日欧は増加傾向だった.米国はアトピー性皮膚炎・食物アレルギーに対するバイオ医薬品,欧州は喘息アプリ,日本はヘルスケアアプリ・疾患横断型等への投資が多く見られた.【考察・結語】アレルギー領域の国内投資環境整備は今後の発展が望まれるものの,米国や欧州が先行している.日本のスタートアップ増加や資金調達の限界を考慮すると,米国等からの資金調達の可能性が検討される.アレルギー研究開発におけるスタートアップの戦略的活性化に寄与する結果と期待される.(著者抄録)

【水疱をきたす疾患】バンコマイシン誘発性線状IgA水疱性皮膚症

小野寺潤一, 足立剛也, 朱瀛瑤, 中村善雄, 高橋勇人, 天谷雅行, 齋藤昌孝

皮膚病診療（(株)協和企画） 46 （ 3 ） 246 - 250 2024年03月

ISSN 0387-7531

＜文献概要＞症例のポイント　・術後敗血症に対するバンコマイシン塩酸塩(VCM)投与後に四肢・体幹と口腔内に緊満性水疱を認め,病歴と精査の結果から,VCM誘発性線状IgA水疱性皮膚症(linear IgA bullous dermatosis:LABD)と診断した.・過去の報告も含めて,VII型コラーゲン特異的IgA ELISAの結果について,VCM中止後の発症早期とVCM中止1ヵ月以降とで比較したところ,後者ではVCM添加下でもELISAが陰性となる症例が多かった.・この結果を踏まえると,発症早期に通常のELISA検査に加えて,VCM添加下でのELISA検査を実施することが重要と考えられた.

Insights from the trends of omalizumab and mepolizumab utilization in patients with asthma: A population-based cohort study using the National Database in Japan

Keiko Kan-o, Tatsuya Noda, Hiroaki Ogata, Katsunori Masaki, Yuichi Nishioka, Tomoya Myojin, Takeya Adachi, Hideaki Morita, Tomoaki Imamura, Mayumi Tamari, Keigo Kainuma

Respiratory Investigation （Elsevier BV） 62 （ 1 ） 113 - 120 2024年01月

ISSN 2212-5345

BACKGROUND: Biologics are increasingly being used in patients with severe uncontrolled asthma. However, the trends in their use for treating severe asthma in Japan remain unclear. METHODS: The number of patients with asthma prescribed omalizumab or mepolizumab between April 2017 and March 2018 was estimated according to sex, age, and geographical region using data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. RESULTS: Overall, 5,014, 3,449 and 7,977 patients were prescribed omalizumab, mepolizumab, or either combination, respectively. The total number of patients prescribed biologics displayed a bimodal distribution with peaks in their early teens and seventies. Biologics were most commonly used by male and female patients in their seventies. Prescription was 1.24 times higher in males than in females up to the teenage years, whereas it was 1.95 times higher in females than in males from their twenties onwards. Omalizumab was prescribed 1.45 times more frequently than mepolizumab, especially in pediatric patients, and was prescribed 1.96 times more often to female patients than to male patients. Regional differences were observed in the proportion of patients prescribed biologics. Correlation analysis suggested a weak relationship (r = 0.3226, p = 0.0270) between the proportion of patients prescribed biologics and board-certified allergists according to the geographic region. CONCLUSIONS: In Japan, biologics are prescribed more often to older patients with severe asthma compared to those in other countries. Thus, eliminating the regional disparities in asthma treatment by specialists is necessary to provide appropriate medical care to patients with severe asthma.

Access to Document (DOI)

[STATE-OF-THE-ART OF GLOBAL START-UP INVESTMENT FOR ALLERGY AND IMMUNOLOGY 2022].

Takeya Adachi, Motoshi Hayano, Yasunori Ito, Takenori Inomata, Yasushi Ogawa, Keigo Kainuma, Keiko Kan-O, Yosuke Kurashima, Yu Kuwabara, Masafumi Sakashita, Sakura Sato, Yasuhiro Tomita, Saeko Nakajima, Masaki Futamura, Katsunori Masaki, Mayumi Tamari, Motohiro Ebisawa, Hideaki Morita

Arerugi = [Allergy] 73 （ 3 ） 268 - 278 2024年

BACKGROUND: In 2022, the "New Capitalism Grand Design and Implementation Plan" was adopted in Japan, emphasizing the promotion and environmental development of startups. Given this context, an investigation into the startup and investment landscape in the allergy sector, both domestically and internationally, becomes imperative. METHODS: We analyzed 156 allergy-related startups from Japan, the US, and Europe from 2010 to 2021. Data on corporate information and investment trends were extracted from databases and VC websites. RESULTS: The total investment reached approximately 7.2 billion USD, with a ratio of 20:6:1 for the US, Europe, and Japan, respectively. The US showed a decline post its peak from 2016-2018, while Europe and Japan experienced growth. Notably, the US primarily invested in biopharmaceuticals for atopic dermatitis and food allergies, Europe in asthma-related apps, and Japan in healthcare apps and cross-border startups. DISCUSSION AND CONCLUSION: While Japan's investment environment in the allergy sector remains in its nascent stages and has room for development, the US and Europe are evidently ahead. Considering the rise of startups and funding limitations in Japan, external funding from regions like the US becomes a potential avenue. These findings are anticipated to contribute to the strategic activation of startups in allergy research and development.

Access to Document (DOI)

[RECURRENT AND VIRTUAL EDUCATION FOR ALL DISCIPLINES AND OCCUPATIONS IN THE ALLERGY REALM : A SURVEY OF THE PARTICIPANTS FROM THE INITIATIVE 'OUTREACH LECTURES' TO CREATE EDUCATIONAL OPPORTUNITIES].

Katsunori Masaki, Masafumi Sakashita, Yasushi Ogawa, Takenori Inomata, Keigo Kainuma, Keiko Kan-O, Sakura Sato, Mayumi Tamari, Saeko Nakajima, Hideaki Morita, Yosuke Kurashima, Masaki Futamura, Koichiro Takahashi, Junji Haruta, Misa Hyakutake, Toshiaki Monkawa, Tamotsu Ishizuka, Yoshimasa Imoto, Noritaka Oyama, Sho Kanzaki, Masanori Kidoguchi, Atsuki Fukushima, Koichi Fukunaga, Shigeharu Fujieda, Motoko Yasutomi, Takeya Adachi

Arerugi = [Allergy] 73 （ 4 ） 329 - 339 2024年

BACKGROUND: In the enhancement of allergy care involving multidisciplinary and multiple medical departments, there is a perceived need for education that targets not only specialists but also non-specialists. However, research on the need for and methods of such education remains inadequate. OBJECTIVE: To design a remote allergy care education program for all medical practitioners and to validate its necessity and utility. METHODS: The Empowering Next Generation Allergist/immunologist toward Global Excellence Task Force (ENGAGE-TF), supported by the Japanese Society of Allergology, initiated a virtual educational program called 'Outreach Lectures' in collaboration with Keio University and Fukui University. This initiative was widely promoted through social media and various institutions, and a survey was conducted through its mailing list. RESULTS: 1139 responses were obtained. More than half were physicians from non-allergy specialties, representing a diverse range of healthcare professions. Over 70% expressed being 'very satisfied,' and over 60% found the difficulty level 'appropriate.' Free-form feedback revealed differences in learning focus based on profession and learning approach based on years of experience. CONCLUSION: The high participation rate (90%) of non-specialist physicians underscores the demand for addressing allergic conditions in primary care. The effectiveness of virtual / recurrent education, particularly for healthcare professionals with over 11 years of experience, was implied. Further follow-up investigation focusing on quantitative and objective assessment of educational effectiveness is indispensable.

Access to Document (DOI)

A case of drug‐induced hypersensitivity syndrome complicated with fulminant type 1 diabetes and type 2 myocardial infarction

Yuki Kobayashi, Takeya Adachi, Hiroki Arakawa, Yugo Minakata, Ken Yajima, Toyoko Inazumi

The Journal of Dermatology 50 （ 12 ） 1603 - 1607 2023年12月

Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is a type of drug eruption that causes multiorgan disorders after the administration of certain drugs such as anticonvulsants. Herein, we report the case of a 66-year-old man with DiHS/DRESS complicated by fulminant type 1 diabetes (FT1D), shock, and cardiac involvement who was treated conservatively without systemic corticosteroid administration. He had taken carbamazepine for trigeminal neuralgia for 7 weeks until he noticed eruptions on his trunk. Two days after admission, he developed diabetic ketoacidosis, resulting in hypovolemic shock. The patient was diagnosed with FT1D, and insulin was administered. Additionally, the patient had a fever over 38°C, elevated white blood cells (>20 000/μL), liver dysfunction, atypical lymphocytes, and lymphadenopathy, but no evidence of viral reactivation. The lymphocyte transformation test for carbamazepine was positive, and human leukocyte antigen typing revealed the A31:01 haplotype, a risk factor for carbamazepine-induced cutaneous adverse drug reactions. Collectively, a diagnosis of atypical DiHS and a definitive case of DRESS was made. Moreover, myocardial dysfunction wall motion was observed. A close examination revealed mild coronary artery stenosis, leading to a diagnosis of type 2 myocardial infarction due to relative ischemia. The patient was carefully monitored without systemic corticosteroid administration because both clinical findings and laboratory data peaked on the same day. The patient's eruption and general condition improved, and he was discharged 4 weeks later. While most cases of DiHS/DRESS with cardiac involvement present with myocarditis, the possibility of ischemic heart disease should be considered in patients with cardiac involvement under shock.

Access to Document (DOI)

Impact of COVID‐19 on care‐seeking patterns for hay fever in Japan: A retrospective claims database cohort study

Yasutsugu Akasaki, Masao Iwagami, Jaemyoung Sung, Ken Nagino, Takeya Adachi, Hideaki Morita, Mayumi Tamari, Keigo Kainuma, Keiko Kan‐o, Hiroaki Ogata, Masafumi Sakashita, Masaki Futamura, Yosuke Kurashima, Saeko Nakajima, Katsunori Masaki, Yasushi Ogawa, Sakura Sato, Akihiro Miyagawa, Akie Midorikawa‐Inomata, Keiichi Fujimoto, Yuichi Okumura, Kenta Fujio, Tianxiang Huang, Kunihiko Hirosawa, Yuki Morooka, Shintaro Nakao, Akira Murakami, Hiroyuki Kobayashi, Takenori Inomata

Allergy （Wiley） 79 （ 4 ） 1056 - 1060 2023年11月

ISSN 0105-4538

Access to Document (DOI)

アレルギー疾患拠点病院ネットワークを活用したアナフィラキシーの全国調査と疾患レジストリーの構築

佐藤さくら, 小太刀豪, 足立剛也, 伊藤靖典, 大嶋勇成, 緒方美佳, 北村勝誠, 鈴木慎太郎, 長尾みづほ, 中野泰至, 福家辰樹, 福冨友馬, 正木克宜, 三浦克志, 森田英明, 矢上晶子, 高橋亨平, 柳田紀之, 海老澤元宏

アレルギー（(一社)日本アレルギー学会） 72 （ 6-7 ） 794 - 794 2023年08月

ISSN 0021-4884

Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges

Takeya Adachi, Ayman W El-Hattab, Ritu Jain, Katya A Nogales Crespo, Camila I Quirland Lazo, Maurizio Scarpa, Marshall Summar, Duangrurdee Wattanasirichaigoon

International Journal of Environmental Research and Public Health 20 （ 6 ） 2023年03月

This document provides a comprehensive summary of evidence on the current situation of rare diseases (RDs) globally and regionally, including conditions, practices, policies, and regulations, as well as the challenges and barriers faced by RD patients, their families, and caregivers. The document builds on a review of academic literature and policies and a process of validation and feedback by a group of seven experts from across the globe. Panelists were selected based on their academic merit, expertise, and knowledge regarding the RD environment. The document is divided into five main sections: (1) methodology and objective; (2) background and context; (3) overview of the current situation and key challenges related to RDs covering six dimensions: burden of disease, patient journey, social impact, disease management, RD-related policies, and research and development; (4) recommendations; and (5) conclusions. The recommendations are derived from the discussion undertaken by the experts on the findings of this review and provide a set of actionable solutions to the challenges and barriers to improving access to RD diagnosis and treatment around the world. The recommendations can support critical decision-making, guiding efforts by a broad range of RDs stakeholders, including governments, international organizations, manufacturers, researchers, and patient advocacy groups.

Access to Document (DOI)

A severe case of hidradenitis suppurativa with chronic anemia treated with adalimumab

Hiroki Arakawa, Takeya Adachi, Yuki Kobayashi, Toyoko Inazumi

The Journal of Dermatology 50 （ 1 ） e22-e23 2023年01月

Access to Document (DOI)

　前のページ - 次のページ　

足立 剛也

論文 - 足立 剛也

足立　剛也

論文 - 足立　剛也